Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies ; volume:9 ; number:1 ; year:2020 ; pages:41-49
Liver cancer ; 9, Heft 1 (2020), 41-49
- Urheber
-
Kariyama, Kazuya
Nouso, Kazuhiro
Wakuta, Akiko
Oonishi, Ayano
Toyoda, Hidenori
Tada, Toshifumi
Hiraoka, Atsushi
Tsuji, Kunihiko
Itobayashi, Ei
Ishikawa, Toru
Takaguchi, Koichi
Tsutsui, Akemi
Shimada, Noritomo
Kumada, Takashi
- DOI
-
10.1159/000502479
- URN
-
urn:nbn:de:101:1-2020020523061474171165
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:04 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kariyama, Kazuya
- Nouso, Kazuhiro
- Wakuta, Akiko
- Oonishi, Ayano
- Toyoda, Hidenori
- Tada, Toshifumi
- Hiraoka, Atsushi
- Tsuji, Kunihiko
- Itobayashi, Ei
- Ishikawa, Toru
- Takaguchi, Koichi
- Tsutsui, Akemi
- Shimada, Noritomo
- Kumada, Takashi
Ähnliche Objekte (12)
Comment on the Manuscript “Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies”
Reply to the Letter “Comment on Regarding Manuscript ‘Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies’”
Curative gene therapies for rare diseases
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Emerging therapies in advanced hepatocellular carcinoma
Microwave ablation of recurrent hepatocellular carcinoma after curative surgical resection
Postoperative complications affect early recurrence of hepatocellular carcinoma after curative resection
The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis
Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
Comment on the Manuscript “Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies”
Reply to the Letter “Comment on Regarding Manuscript ‘Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies’”
Curative gene therapies for rare diseases
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Emerging therapies in advanced hepatocellular carcinoma
Microwave ablation of recurrent hepatocellular carcinoma after curative surgical resection
Postoperative complications affect early recurrence of hepatocellular carcinoma after curative resection
The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis
Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
Comment on the Manuscript “Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies”
Reply to the Letter “Comment on Regarding Manuscript ‘Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies’”
Curative gene therapies for rare diseases
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Emerging therapies in advanced hepatocellular carcinoma
Microwave ablation of recurrent hepatocellular carcinoma after curative surgical resection
Postoperative complications affect early recurrence of hepatocellular carcinoma after curative resection
The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis
Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment